Table 3.
Prevalence of endocrine-related immune-related adverse events after treatment with various immune checkpoint inhibitors.
| Ipilimumab and PD-1 inhibitors (n=25) |
Nivolumab (n=189) |
Pembrolizumab (n=162) |
Atezolizumab (n=73) |
Dulbumumab (n=13) |
Avelumab (n=4) |
|
|---|---|---|---|---|---|---|
| Endocrine-related irAEs (%) | 52.0 | 23.3 | 22.8 | 30.1 | 7.7 | 50.0 |
| Any hypothyroidism (%) | 52.0 | 22.8 | 20.4 | 28.8 | 7.7 | 50.0 |
| Destructive thyroiditis (%) | 24.0 | 5.3 | 8.6 | 16.4 | 7.7 | 25.0 |
| Asymptomatic hypothyroidism (%) | 24.0 | 17.5 | 10.5 | 12.3 | 0 | 0 |
| Secondary hypothyroidism (%) | 0 | 0 | 1.23 | 0 | 0 | 0 |
| Any hypoadenocorticism (%) | 20.0 | 0.5 | 3.1 | 4.1 | 0 | 25.0 |
| Primary hypoadrenocorticism (%) | 0 | 0 | 1.2 | 1.4 | 0 | 0 |
| ACTH isolated deficiency (%) | 12.0 | 0.5 | 2.5 | 2.7 | 0 | 0 |
| Hypopituitarism (%) | 12.0 | 0 | 0 | 0 | 0 | 25.0 |
| Insulin-dependent diabetes (%) | 0 | 1.1 | 1.9 | 10 | 0 | 0 |
irAE, immune-related adverse events; PD-1, programmed cell death protein 1; PD-L1, programmed cell death protein 1 ligand 1; ACTH, adrenocorticotropic hormone.